Prediction of RA early arthritis & clinically suspect arthralgia pts w/ AI analysis of MRIs scans: ✔️Feasible ✔️Accurate AUC 0.683 EA group AUC 0.727 CSA group ✔️Peformance = human experts ✚ Could identify new imaging biomarkers https://t.co/sVXw9A8NqZ OP0002 #EULAR23 @Rheumnow https://t.co/oq5RJApm9U

• EULAR Abstract Archive

Provan et al. large scandinavian registry study: 🫁ILD risk in RA & PsA initiating b/tsDMARDs HR ILD RA=10 HR ILD PsA=5 No increase risk w/ MTX and b/tsDMARDs but RA HR ILD 1.7 RTX vs. ETA: confounding by indication? https://t.co/CF1ysNkQxU OP0006 #EULAR23 @Rheumnow https://t.co/DgDE1uFeUs

• EULAR Abstract Archive

Autoimmune disease diagnoses slowly on the rise, despite reduced smoking - but that’s now 10% of the population, & many patients have more than one. Most are lifelong. Surely this needs more investment?? CPRD data from the UK #EULAR2023 OP0007 @RheumNow https://t.co/7NGF5YaE9z https://t.co/m6SaibqmEq

• https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00457-9

Scandinavian RA registry study shows reassuring data on CV risk in RA🫀 Acute Coronary Syndrom incidence rates are similar in RA pts achieving remission & general pop & is similar whether RA pts reach remission using MTX or TNFi. https://t.co/wBDZtaTVba OP0038 #EULAR23 @Rheumnow https://t.co/JLdbYF49xF

• EULAR Abstract Archive

Data from combined big Scandinavian population registries looking at both RA and PsA, ILD development, & MTX exposure Here’s the ILD risk for methotrexate. Can we stop this MTX misinformation? No more besmirching a really useful drug for our patients #EULAR2023 OP0006 @RheumNow https://t.co/7swqAYchDC

Interstitial lung disease in RA and PSA in b/tsDMARD treated patients with MTX - there is no increased risk of developing ILD above the background risk of RA and PsA vs general population Sella Aarrestad Provan Abst#OP0006 @RheumNow https://t.co/yJsrmraeZ5

Comorbidities and metabolic burden in PsA: -Occur EARLY -Early PsA pts > multiple comorbidities & > CV morbidity vs. age-matched early RA pts Independent of BMI & obesity Time to address these as part of dis pathogenesis in PsA https://t.co/qOiGHn2eZT OP0066 #EULAR23 @Rheumnow https://t.co/lK7MbeMybO

• EULAR Abstract Archive

New benefit/risk outlook 👀 on ORAL surveillance 2 subgrps: 🟢RA w/ no previous Hx of atherosclerotic CV dis = TOFA at least as good as TNFi AND risk of MACE is comparable 🛑RA w/ HxASCVD = efficacy TOFA = TNFi AND > risk of MACE https://t.co/VOxNQSoyY4 OP0043 #EULAR23 @Rheumnow https://t.co/m98eSMG03U

• EULAR Abstract Archive

Leiden arthritis clinic: 1000+ pts w/ RA & high BMI associated w/ < MRI-detected osteitis at dis onset but NOT synovitis RA w/ overweight/obesity 25% < MRI-detected erosive progression at 2 yrs More marked in ACPA+ pts Is leptin the missing link? 🤓 OP0039 #EULAR23 @Rheumnow https://t.co/RRSV9VlRtn

Biosimilar vs originator: as switches loom in the US, once again it’s really hard to say we see any differences in drug survival for our RA patients These data from forced switching in BC, Canada are just like the others - biosimilars are business as usual. POS0567 #EULAR2023 https://t.co/Ebl1hTM4qE

Ongoing work to #classify #inflammatory #arthritis in Pts using #check #point #inhibitors. A 1st step to study the etiology of immune changes from these life prolonging medications #EULAR2023 @RheumNow https://t.co/Bv1q8IphqF

• https://twitter.com/drdavidliew/status/1663889739307704324

Can #machine #learning replace #rheumatologists? OP0190 #EULAR23 #Machine learning can help determine who will develop #rheumatoidarthritis in Pts with #arthralgia but the real study could be ask #clinician the #probability of RA and do #AI and see comparative accuracy @RheumNow

When does RA get complicated? Many things can burden our patients, making their RA difficult to treat #EULAR2023 @RheumNow https://t.co/FM1UCNbmKr